GlassScriptPhysician profile
Ashfaq A Tapia
NPI 1295997930
$4,050.27
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,693 · 2020: $213 · 2021: $587 · 2022: $836 · 2023: $540 · 2024: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $772.23 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $508.42 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $381.47 | 2019-2023 | Emgality, Jardiance |
| Astrazeneca Pharmaceuticals LP | $379.06 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $314.57 | 2019-2023 | |
| Abbvie INC. | $250.78 | 2021-2023 | Ubrelvy, Qulipta, Viberzi |
| Amgen INC. | $243.32 | 2019-2024 | Krystexxa, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $187.87 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Mylan Specialty L.P. | $158.14 | 2019-2021 | |
| Pfizer INC. | $130.27 | 2019-2021 | |
| Allergan, INC. | $126.27 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $93.38 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $77.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.92 | 2021 | |
| Astellas Pharma US INC | $50.45 | 2022-2024 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38.88 | 2019-2022 | |
| Radius Health, INC. | $35.25 | 2019 | |
| Dexcom, INC. | $33.00 | 2023-2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $30.94 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.21 | 2019 | |
| Esperion Therapeutics, INC. | $27.53 | 2021 | |
| Currax Pharmaceuticals LLC | $27.40 | 2022 | |
| Scilex Pharmaceuticals INC. | $20.16 | 2024 | |
| Amarin Pharma, INC. | $17.35 | 2022 | |
| Horizon Therapeutics Plc | $15.96 | 2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $14.38 | 2023 | |
| Axonics, INC. | $13.04 | 2023 | Axonics |
| Nalpropion Pharmaceuticals LLC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashfaq Tapia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.